BRENTWOOD, TN / ACCESSWIRE / April 11, 2023 / The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.A burgeoning sector within biotech is the cell...

Vertex shares are on the rise.Vertex Pharmaceuticals (NASDAQ: VRTX) has been generating billion-dollar revenue for years, thanks to its portfolio of cystic fibrosis (CF) drugs. In fact, Vertex is the global leader in CF treatment and likely to hang onto that position for quite some time. But soon, ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertexs...

CRISPR Therapeutics AG (NASDAQ:CRSP Get Rating) has been assigned a consensus rating of Hold from the twenty research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and nine have ...

CRISPR Therapeutics AG (NASDAQ:CRSP Get Rating) has been assigned an average rating of Hold from the seventeen brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and eight have ...